Safety Evaluation of GX-12. A New DNA Vaccine for HIV Infection in Rodents

Drug and Chemical Toxicology

Volumn 26, Issue 4, 2003, Pages 271-284

  Choi, Seul Min ^a   Lee, Dong Sop ^a   Son, Mi Kyung ^a   Sohn, Young Sung ^a   Kang, Kyung Koo ^a   Kim, Chae Young ^a   Kim, Byung Moon ^a   Kim, Won Bae ^a  

^a Dong A Pharmaceutical Company   (South Korea)

Author keywords

Acute subacute toxicity; Autoantibody; Autoimmunity; DNA vaccine; GX 12

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMYLASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; DNA ANTIBODY; DNA VACCINE; GLUCOSE; GX 12; MYOSIN ANTIBODY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; FOOD INTAKE; GLOMERULONEPHRITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; MYOSITIS; NONHUMAN; ORGAN WEIGHT; RAT; STATISTICAL ANALYSIS; URINALYSIS; VACCINATION;

AIDS VACCINES; ANIMALS; AUTOANTIBODIES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; MYOSINS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, SPRAGUE-DAWLEY; VACCINES, DNA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; RODENTIA;

EID: 0142075186     PISSN: 01480545     EISSN: None     Source Type: Journal    
DOI: 10.1081/DCT-120024842     Document Type: Article

References (22)

1. Cichutek, K. DNA vaccines: development, standardization, and regulation. Intervirology 2000, 43 (4-6), 331-338.
2. Leitner, W.W.; Ying, H.; Restifo, N.P. DNA and RNA-based vaccines: principles, progress, and prospects. Vaccine 2000, 18 (9-10), 765-777.
3. Tang, D.C.; DeVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356 (6365), 152-154.
4. Sharma, A.K.; Khuller, G.K. DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol. Cell Biol. 2001, 79 (6), 537-546.
5. Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S. ; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220 (4599), 868-871.
6. Gotch, F.M.; Imami, N.; Hardy, G. Candidate vaccines for immunotherapy in HIV. HIV Medicine 2001, 2 (4), 260-265.
7. Bojak, A.; Deml, L.; Wagner, R. The past, present, and future of HIV-vaccine development: a critical view. Drug Discov. Today 2002, 7 (1), 36-46.
8. Egan, M.A.; Charini, W.A.; Kuroda, M.J.; Schmitz, J.E.; Racz, P.; Tenner-Racz, K.; Manson, K.; Wyand, M.; Lifton, M.A.; Nickerson, C.E.; Fu, T.; Shiver, J.W.; Letvin, N.L. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J. Virol. 2000, 74 (16), 7485-7495.
9. Gorelick, R.J.; Benveniste, R.E.; Lifson, J.D.; Yovandich, J.L.; Morton, W.R.; Kuller, L.; Flynn, B.M.; Fisher, B.A.; Rossio, J.L.; Piatak, M., Jr.; Bess, J.W., Jr.; Henderson, L.E.; Arthur, L.O. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J. Virol. 2000, 74 (24), 11935-11949.
10. Davis, N.L.; Caley, I.J.; Brown, K.W.; Betts, M.R.; Irlbeck, D.M.; McGrath, K.M.; Connell, M.J.; Montefiori, D.C.; Frelinger, J.A.; Swanstrom, R.; Johnson, P.R.; Johnston, R.E. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 2000, 74 (1), 371-378.
11. Murphy, C.G.; Lucas, W.T.; Means, R.E.; Czajak, S.; Hale, C.L.; Lifson, J.D.; Kaur, A.; Johnson, R.P.; Knipe, D.M.; Desrosiers, R.C. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol. 2000, 74 (17), 7745-7754.
12. Ourmanov, I.; Brown, C.R.; Moss, B.; Carroll, M.; Wyatt, L.; Pletneva, L.; Goldstein, S.; Venzon, D.; Hirsch, V.M. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 2000, 74 (6), 2740-2751.
13. Dolin, R.; Graham, B.S.; Greenberg, S.B.; Tacket, C.O.; Belshe, R.B.; Midthun, K.; Clements, M.L.; Gorse, G.J.; Horgan, B.W.; Atmar, R.L. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann. Intern. Med. 1991, 114 (2), 119-127.
14. Francis, D.P.; Gregory, T.; McElrath, M.J.; Belshe, R.B.; Gorse, G.J.; Migasena, S.; Kitayaporn, D.; Pitisuttitham, P.; Matthews, T.; Schwartz, D.H.; Berman, P.W. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res. Hum. Retroviruses 1998, 14 (Suppl 3), 325-331.
15. Klinman, D.M.; Takeshita, F.; Kamstrup, S.; Takeshita, S.; Ishii, K.; Ichino, M.; Yamada, H. DNA vaccines: capacity to induce auto-immunity and tolerance. Dev. Biol. (Basel) 2000, 104, 45-51.
16. Mor, G. Plasmid DNA: a new era in vaccinology. Biochem. Pharmacol. 1998, 55 (8), 1151-1153.
17. Gilkeson, G.S.; Riuz, P.; Howell, D.; Lefkowith, J.B.; Pisetsky, D.S. Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. Clin. Immunol. Immunopathol. 1993, 68 (3), 283-292.
18. Sambrook, J.; Frisch, E.F.; Maniatis, T. Molecular cloning. In A Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratories Press: New York, 1989.
19. Mor, G.; Singla, M.; Steinberg, A.D.; Hoffman, S.L.; Okuda, K.; Klinman, D.M. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 1997, 8 (3), 293-300.
20. Boei, J.J.; Natarajan, A.T. Classification of X-ray-induced Robertsonian fusion-like configurations in mouse splenocytes. Int. J. Radiat. Biol. 1996, 69 (4), 421.-427.
21. Robertson, J.S.; Griffiths, E. Assuring the quality, safety, and efficacy of DNA vaccines. Mol. Biotechnol. 2001, 17 (2), 143-149.
22. Robertson, J.S. Safety consideration for nucleic acid vaccines. Vaccine 1994, 12 (16), 1526-1528.